Citrullination at the Inflammatory Skin Barrier
New to Baricitinib? There is a guide in the encyclopedia. Read the guide →
Studysummary This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study "Citrullination at the Inflammatory Skin Barrier" investigates the role of PADI1 in atopic dermatitis (AD). It reveals that PADI1 expression is reduced in AD-affected skin, leading to decreased citrullination of proteins crucial for skin barrier function. Baricitinib, a JAK1/2 inhibitor, can counteract this reduction, suggesting a therapeutic potential. The research indicates that restoring PADI1 expression might improve skin barrier function in AD, though the impact on enzyme activity is still uncertain. Future studies may look into drug combinations to boost PADI1 expression and activity, offering new treatment possibilities for inflammatory skin conditions.
